Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F. Rossignol P, et al. Circulation. 2012 Jan 17;125(2):271-9. doi: 10.1161/CIRCULATIONAHA.111.028282. Epub 2011 Nov 29. Circulation. 2012. PMID: 22128223 Clinical Trial.
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Olivier A, Girerd N, Michel JB, Ketelslegers JM, Fay R, Vincent J, Bramlage P, Pitt B, Zannad F, Rossignol P; EPHESUS Investigators. Olivier A, et al. Among authors: rossignol p. Int J Cardiol. 2017 Aug 15;241:344-350. doi: 10.1016/j.ijcard.2017.02.018. Epub 2017 Feb 8. Int J Cardiol. 2017. PMID: 28284500 Clinical Trial.
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial.
Ferreira JP, Cleland JGF, Girerd N, Pellicori P, Hazebroek MR, Verdonschot J, Collier TJ, Petutschnigg J, Clark AL, Staessen JA, Heymans S, Zannad F, Rossignol P. Ferreira JP, et al. Among authors: rossignol p. Clin Res Cardiol. 2023 Feb;112(2):330-332. doi: 10.1007/s00392-022-02116-w. Epub 2022 Oct 24. Clin Res Cardiol. 2023. PMID: 36279002 Free article. No abstract available.
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, Solomon SD, Pitt B, Pfeffer MA, Shah AM, Petutschnigg J, Pieske B, Edelmann F, Zannad F. Ferreira JP, et al. Among authors: rossignol p. Eur J Heart Fail. 2023 Jan;25(1):108-113. doi: 10.1002/ejhf.2726. Epub 2022 Nov 9. Eur J Heart Fail. 2023. PMID: 36303266 Free article.
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial).
Ferreira JP, Cleland JGF, Girerd N, Pellicori P, Hazebroek MR, Verdonschot J, Collier TJ, Petutschnigg J, Clark AL, Staessen JA, Heymans S, Rossignol P, Zannad F. Ferreira JP, et al. Among authors: rossignol p. Am J Cardiol. 2023 Mar 15;191:39-42. doi: 10.1016/j.amjcard.2022.12.016. Epub 2023 Jan 10. Am J Cardiol. 2023. PMID: 36634548 Free article. Clinical Trial.
696 results